Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quest For ‘It Factor’ Continues In Competition For EMA After Brexit

Executive Summary

The many cities that want to host the European Medicines Agency when it moves from London to another member state in light of Brexit are working hard to come up with a determining factor that will make them the obvious choice. It may on the surface seem strange, but Ireland is making much of the fact that if its capital city Dublin were chosen, existing EMA staff wouldn’t need to move there.

You may also be interested in...

Suspense Continues Over Formal EMA Hosting Criteria, October Decision On New Home Likely

The criteria for cities wanting to host the European Medicines Agency post Brexit should be formally agreed in June and the agency’s new location could be decided in October. There are concerns that, if the decision is left any longer, it will be hard for the EMA to move in the time remaining before the UK leaves the EU.

Race Hots Up For EMA After Brexit

France has officially named Lille as the city it would like to host the European Medicines Agency once the UK leaves the EU, and Italy has appointed an ambassador to promote Milan’s bid for the agency. Meanwhile, stakeholders in Denmark are joining forces to stress why Copenhagen would be a good choice, and Ireland, the Netherlands and Austria have all confirmed their candidacies.

EU Accelerated Assessment Tracker

Marinus’s ganaxolone has lost its accelerated assessment status mid-review at the European Medicines Agency while Roche’s glofitamab will be fast-tracked once a filing has been made.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts